They are a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using their lead investigational new drug product, AD04, a selective serotonin-3 antagonist.
$5.00 - $5.00
Joseph Gunnar & Co.
To view the prospectus for Adial Pharmaceuticals IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277